Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

hen used together," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Through our portfolio of high blood pressure medications, Novartis is committed to providing physicians with a wide range of tools to help patients lower their blood pressure."

About Tekturna

Tekturna received FDA approval in March 2007 for the treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. Tekturna was developed in collaboration with Speedel.

In clinical trials, the approved doses of Tekturna were generally well tolerated and the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash.

Angioedema has been rarely reported in patients taking Tekturna.

About Diovan

Novartis remains at the forefront of cardiovascular medicine through development of innovative products like DIOVAN, the most-prescribed member of the ARB class (angiotensin receptor blocker) in the world today. DIOVAN is available for the treatment of high blood pressure in more than 100 countries, for the treatment of heart attack survivors in more than 70 countries and in more than 90 countries for the treatment of people with heart failure.

DIOVAN is contraindicated in patients who are hypersensitive to any component of this product.

Volume and or salt depletion should be corrected in patients prior to administering DIOVAN or symptomatic hypotension may occur.

Care should be exercised with dosing of DIOVAN in patients with severe renal impairment. As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be observed in susceptible individuals (e.g. patients with renal artery stenosis or severe heart failure).

No significant differences b
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:3/4/2015)... , March 4, 2015  Results of the ... Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection ... session at the 32 nd Annual Miami Breast ... conducted by Moshe Papa , MD, FACS, Professor ... Tel Aviv University, reports an analysis of MarginProbe,s efficiency ...
(Date:3/4/2015)... , March 4, 2015   HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled ... at 8:00 a.m. Eastern Time on Tuesday, March 10, ... the Loews Miami Beach Hotel in Florida ...
(Date:3/4/2015)... Deutschland, 4. März 2015 TeraRecon, ... medizinischen Bildmanagementlösungen für Unternehmen, baut seine Präsenz ... Sternberg zum Director of Sales und ... weiter aus. Logo - ... ist für den Verkauf und die ...
Breaking Medicine Technology:New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast 2TeraRecon baut seine Präsenz in EMEA aus 2TeraRecon baut seine Präsenz in EMEA aus 3
... publishing and,information services company focused on market research ... the Asia-Pacific region is grabbing an,increasing share of ... changes across the region, has already been growing ... to the new 160-plus page report from CenterWatch ...
... In response to the growing,need for competent ... certificate program in Clinical Research and Regulatory,Administration ... of Continuing Studies (SCS), in,partnership with Northwestern ... launch the new program this spring with ...
Cached Medicine Technology:Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report 2Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report 3Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program 2
(Date:3/4/2015)... (PRWEB) March 04, 2015 The federal ... allege the statin drug caused patients to develop Type ... District Court, District of South Carolina. According to court ... on March 26, 2015 at 10:00 a.m. In advance ... submit a Joint Status report to the Court by ...
(Date:3/4/2015)... The ability of volumetric breast imaging ... help improve breast cancer risk prediction models is ... at the European Congress of Radiology (ECR) meeting, ... posters and 2 session presentations - highlight the ... quantitative breast imaging software tools to provide insight ...
(Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
(Date:3/4/2015)... March 04, 2015 The print component ... The San Francisco Chronicle with a circulation of approximately ... Its digital component is distributed nationally through a vast ... news sites and partner outlets. To explore the digital ... , Milorganite is composed of heat-dried microbes that have ...
(Date:3/4/2015)... The Global Liquefied Petroleum Gas Market was ... estimated to grow to $288.7 billion by 2019, ... 2019. , Browse through the TOC of Global ... industry trends, segments & forecasts., http://www.micromarketmonitor.com/market-report/liquid-petroleum-gas-reports-5046983367.html ... is classified into source, application, and region. The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Starting the morning of Feb. 1, two,giant heart-shaped ... of,Michigan,s downtown Detroit headquarters building and remind women to ... February, the 11-story high heart displays will adorn both,the ... on East,Lafayette near I-375 in downtown Detroit. The large ...
... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
... of Alabama at Birmingham have uncovered important new information about ... replicate and wreak havoc on the immune system. , The ... viruses work to subvert the immune system, the researchers say. ... used to develop new drugs to combat a variety of ...
... most hospitals already stocked with simple, inexpensive solution , , THURSDAY, ... (magnesium sulfate) given just before delivery to pregnant women at ... palsy among these newborns in half, U.S. researchers report. , ... United States. All the women were at high risk for ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... Jan. 31 MQ Associates, Inc. ("MQ,Associates") announced ... tender offer and consent solicitation with respect to ... (CUSIP No. 55345RAC2) (the "Notes").,The tender offer and ... on January 29, 2008 (the "Expiration Date")., ...
Cached Medicine News:Health News:Heart-Shaped Light Displays on Blue Cross Blue Shield of Michigan Building Show Support for American Heart Month, National Wear Red Day 2Health News:Oregon researchers find trigger gene for muscle development 2Health News:Researchers uncover more about how poxviruses evade the immune system 2Health News:Researchers uncover more about how poxviruses evade the immune system 3Health News:Epsom Salt Cut Cerebral Palsy Rate in Half Among Preemies 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 3
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
Round knurled handle. Overall length 130 mm....
4.625 inches, curved blade 4 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: